WO2002064819A1 - Novel assay method - Google Patents
Novel assay method Download PDFInfo
- Publication number
- WO2002064819A1 WO2002064819A1 PCT/JP2002/001173 JP0201173W WO02064819A1 WO 2002064819 A1 WO2002064819 A1 WO 2002064819A1 JP 0201173 W JP0201173 W JP 0201173W WO 02064819 A1 WO02064819 A1 WO 02064819A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reaction system
- dehydrogenase
- test substance
- phosphodalconate
- measuring
- Prior art date
Links
- 238000003556 assay Methods 0.000 title abstract 3
- 238000006243 chemical reaction Methods 0.000 claims abstract description 45
- 238000012360 testing method Methods 0.000 claims abstract description 29
- 239000000126 substance Substances 0.000 claims abstract description 28
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 24
- 239000008103 glucose Substances 0.000 claims abstract description 22
- 239000005515 coenzyme Substances 0.000 claims abstract description 19
- 239000012472 biological sample Substances 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 24
- 239000003153 chemical reaction reagent Substances 0.000 claims description 23
- 206010018910 Haemolysis Diseases 0.000 claims description 16
- 230000008588 hemolysis Effects 0.000 claims description 16
- 101710088194 Dehydrogenase Proteins 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 10
- 150000002402 hexoses Chemical class 0.000 claims description 10
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 9
- 239000003925 fat Substances 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 8
- 230000002949 hemolytic effect Effects 0.000 claims description 7
- 238000000691 measurement method Methods 0.000 claims description 7
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical compound NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims description 6
- CXONXVMMINSQBV-NNYOXOHSSA-N (2r,3r,4s,5r)-5-[[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-2-(3-carbamothioylpyridin-1-ium-1-yl)-4-hydroxyoxolan-3-olate Chemical compound NC(=S)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)[O-])=C1 CXONXVMMINSQBV-NNYOXOHSSA-N 0.000 claims description 4
- 108010044467 Isoenzymes Proteins 0.000 claims description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims description 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 102000004420 Creatine Kinase Human genes 0.000 claims description 3
- 108010042126 Creatine kinase Proteins 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- 235000006408 oxalic acid Nutrition 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000004382 Amylase Substances 0.000 claims description 2
- 102000013142 Amylases Human genes 0.000 claims description 2
- 108010065511 Amylases Proteins 0.000 claims description 2
- 235000019418 amylase Nutrition 0.000 claims description 2
- 239000012491 analyte Substances 0.000 claims 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 abstract description 7
- 239000012467 final product Substances 0.000 abstract description 3
- BIRSGZKFKXLSJQ-SQOUGZDYSA-N 6-Phospho-D-gluconate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O BIRSGZKFKXLSJQ-SQOUGZDYSA-N 0.000 abstract 4
- 102000004567 6-phosphogluconate dehydrogenase Human genes 0.000 abstract 2
- 108020001657 6-phosphogluconate dehydrogenase Proteins 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 abstract 1
- 238000005259 measurement Methods 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 102100028207 6-phosphogluconate dehydrogenase, decarboxylating Human genes 0.000 description 11
- 101710151348 D-3-phosphoglycerate dehydrogenase Proteins 0.000 description 11
- 101710125031 6-phosphogluconate dehydrogenase, NAD(+)-dependent, decarboxylating Proteins 0.000 description 10
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 10
- 239000000523 sample Substances 0.000 description 8
- 102000001554 Hemoglobins Human genes 0.000 description 7
- 108010054147 Hemoglobins Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000006911 enzymatic reaction Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 239000000203 mixture Substances 0.000 description 3
- 102000002281 Adenylate kinase Human genes 0.000 description 2
- 108020000543 Adenylate kinase Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- KDRNOBUWMVLVFH-UHFFFAOYSA-N 2-methyl-n-(2,2,6,6-tetramethylpiperidin-4-yl)prop-2-enamide Chemical compound CC(=C)C(=O)NC1CC(C)(C)NC(C)(C)C1 KDRNOBUWMVLVFH-UHFFFAOYSA-N 0.000 description 1
- 101000740112 Homo sapiens Membrane-associated transporter protein Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 102100037258 Membrane-associated transporter protein Human genes 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- 241000047703 Nonion Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000003366 endpoint assay Methods 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 102000010705 glucose-6-phosphate dehydrogenase activity proteins Human genes 0.000 description 1
- 108040005050 glucose-6-phosphate dehydrogenase activity proteins Proteins 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000003318 immunodepletion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 238000011545 laboratory measurement Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
Definitions
- FIG. 4 is a graph showing a change in absorbance of hemolyzed blood in a NADP reaction system (Example 1).
- hemolysis interference In a reaction system that measures hexose or hexose phosphorylated by a coenzyme, when hemolysis occurs in the sample, there is a phenomenon that gives a positive error to the measurement value.This phenomenon is called hemolysis interference. .
- the blood was centrifuged at 3000 rpm to obtain human red blood cells.
- the erythrocytes were frozen at 120 ° C and further lysed at room temperature. As a result, the blood cells burst and a hemolytic component was obtained. This was diluted with physiological saline to make hemoglobin 500 mg / dL.
- the following reagents were prepared.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002565130A JP4106270B2 (ja) | 2001-02-14 | 2002-02-13 | 新規測定方法 |
EP02712305A EP1361283A4 (en) | 2001-02-14 | 2002-02-13 | NEW ASSAY PROCEDURE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001036863 | 2001-02-14 | ||
JP2001-036863 | 2001-02-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002064819A1 true WO2002064819A1 (en) | 2002-08-22 |
Family
ID=18900077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/001173 WO2002064819A1 (en) | 2001-02-14 | 2002-02-13 | Novel assay method |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1361283A4 (ja) |
JP (1) | JP4106270B2 (ja) |
KR (1) | KR100836179B1 (ja) |
CN (1) | CN1228636C (ja) |
TW (1) | TWI275795B (ja) |
WO (1) | WO2002064819A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1388735A1 (en) * | 2002-08-09 | 2004-02-11 | Sysmex Corporation | Reagent for assaying lipids |
CN101324613A (zh) * | 2007-06-13 | 2008-12-17 | 苏州艾杰生物科技有限公司 | 无机磷诊断/测定试剂盒及无机磷的浓度测定方法 |
WO2011136063A1 (ja) * | 2010-04-30 | 2011-11-03 | 日東紡績株式会社 | 特定物質の測定方法および特定物質測定用キット |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100430487C (zh) * | 2002-11-15 | 2008-11-05 | 江西特康科技有限公司 | 单一稳定烟酰胺辅酶液体试剂的制备方法 |
US20160312208A1 (en) * | 2013-12-17 | 2016-10-27 | Siemens Healthcare Diagnostics Inc. | Preparation of multi-hapten mutant g6pdh conjugates and their use for detection of multiple analytes |
CN105699640B (zh) * | 2014-05-07 | 2017-06-06 | 北京中生金域诊断技术股份有限公司 | 一种检测肠道屏障功能的试剂盒 |
CN115078341B (zh) * | 2022-08-22 | 2022-11-29 | 上海执诚生物科技有限公司 | 一种用于检测葡萄糖-6-磷酸脱氢酶的试剂及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3509025A (en) * | 1951-01-28 | 1970-04-28 | Boehringer Mannheim Gmbh | Method and agent for the enzymatic determination of glucose |
JPH01112999A (ja) * | 1988-06-07 | 1989-05-01 | Mitsubishi Petrochem Co Ltd | グルコース測定用組成物 |
EP0469154A1 (en) * | 1990-02-20 | 1992-02-05 | Iatron Laboratories, Inc. | Method of determining glucose-6-phosphate and composition therefor |
JPH07250698A (ja) * | 1995-03-15 | 1995-10-03 | Unitika Ltd | 分析用試薬と分析方法 |
JPH10327896A (ja) * | 1996-12-26 | 1998-12-15 | Nitto Boseki Co Ltd | 共役脱水素酵素反応の停止剤、停止方法および特定物質の測定方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1318568A (en) * | 1970-09-17 | 1973-05-31 | Miles Lab | Colourimetric assay of dehydrogenases |
US3956069A (en) * | 1974-04-29 | 1976-05-11 | Abbott Laboratories | Enzymatic assays for glucose, creatine phosphokinase or plasma ammonia |
DE3303098A1 (de) * | 1983-01-31 | 1984-08-02 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren und reagenz zur glucosebestimmung im haemolysierten blut |
CA2144174A1 (en) * | 1992-09-14 | 1994-03-31 | Jianmin Bao | Electrophoretically mediated chemical analysis |
JP3685268B2 (ja) * | 1995-03-10 | 2005-08-17 | 東洋紡績株式会社 | α−アミラーゼ活性測定法および測定試薬組成物 |
DE19756238A1 (de) * | 1996-12-26 | 1998-07-02 | Nitto Boseki Co Ltd | Unterbrecher für die Konjugationsdehydrogenasereaktion, Unterbrechungsverfahren und Verfahren zur Messung einer spezifischen Substanz |
US5801006A (en) * | 1997-02-04 | 1998-09-01 | Specialty Assays, Inc. | Use of NADPH and NADH analogs in the measurement of enzyme activities and metabolites |
US6162618A (en) * | 1998-04-10 | 2000-12-19 | Smithkline Beecham Corporation | 6-phosphogluconate dehydrogenase of Streptococcus pneumoniae |
-
2001
- 2001-12-31 TW TW090133584A patent/TWI275795B/zh not_active IP Right Cessation
-
2002
- 2002-01-08 KR KR1020020000955A patent/KR100836179B1/ko not_active Expired - Fee Related
- 2002-02-09 CN CNB021045992A patent/CN1228636C/zh not_active Expired - Lifetime
- 2002-02-13 JP JP2002565130A patent/JP4106270B2/ja not_active Expired - Fee Related
- 2002-02-13 WO PCT/JP2002/001173 patent/WO2002064819A1/ja not_active Application Discontinuation
- 2002-02-13 EP EP02712305A patent/EP1361283A4/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3509025A (en) * | 1951-01-28 | 1970-04-28 | Boehringer Mannheim Gmbh | Method and agent for the enzymatic determination of glucose |
JPH01112999A (ja) * | 1988-06-07 | 1989-05-01 | Mitsubishi Petrochem Co Ltd | グルコース測定用組成物 |
EP0469154A1 (en) * | 1990-02-20 | 1992-02-05 | Iatron Laboratories, Inc. | Method of determining glucose-6-phosphate and composition therefor |
JPH07250698A (ja) * | 1995-03-15 | 1995-10-03 | Unitika Ltd | 分析用試薬と分析方法 |
JPH10327896A (ja) * | 1996-12-26 | 1998-12-15 | Nitto Boseki Co Ltd | 共役脱水素酵素反応の停止剤、停止方法および特定物質の測定方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1361283A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1388735A1 (en) * | 2002-08-09 | 2004-02-11 | Sysmex Corporation | Reagent for assaying lipids |
CN101324613A (zh) * | 2007-06-13 | 2008-12-17 | 苏州艾杰生物科技有限公司 | 无机磷诊断/测定试剂盒及无机磷的浓度测定方法 |
WO2011136063A1 (ja) * | 2010-04-30 | 2011-11-03 | 日東紡績株式会社 | 特定物質の測定方法および特定物質測定用キット |
JPWO2011136063A1 (ja) * | 2010-04-30 | 2013-07-18 | 日東紡績株式会社 | 特定物質の測定方法および特定物質測定用キット |
Also Published As
Publication number | Publication date |
---|---|
JPWO2002064819A1 (ja) | 2004-06-17 |
KR20020066953A (ko) | 2002-08-21 |
EP1361283A4 (en) | 2004-03-17 |
KR100836179B1 (ko) | 2008-06-09 |
JP4106270B2 (ja) | 2008-06-25 |
EP1361283A1 (en) | 2003-11-12 |
TWI275795B (en) | 2007-03-11 |
CN1370994A (zh) | 2002-09-25 |
CN1228636C (zh) | 2005-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5301156B2 (ja) | 全血を用いる血液成分測定方法及び測定キット | |
JP5906604B2 (ja) | 全血検体の成分測定方法 | |
JP5004367B2 (ja) | 軽症耐糖能異常またはインスリン分泌不全の検出方法 | |
WO2002064819A1 (en) | Novel assay method | |
Orfanos et al. | A rapid screening test for Duchenne muscular dystrophy using dried blood specimens | |
WO1992020817A1 (en) | High precision determination of d-glucose-6-phosphate and composition therefor | |
CN111455020A (zh) | 一种1,5-脱水山梨醇检测试剂盒及检测方法 | |
JP4217815B2 (ja) | グルコースデヒドロゲナーゼによるグルコースの定量方法およびグルコース定量用試薬 | |
JP6522466B2 (ja) | オートタキシンの活性測定方法 | |
JP3034987B2 (ja) | D−グリセロアルデヒド−3−リン酸、無機リン、または1,3−ジホスホグリセリン酸の高感度定量法および定量用組成物 | |
JP3750955B2 (ja) | クレアチンキナーゼまたはそのmbアイソザイムの定量用乾式分析素子 | |
JP2005304483A (ja) | アルカリフォスファターゼ測定法 | |
US3293146A (en) | Composition for detecting guanase and process for diagnosing viral hepatitis therewith | |
JP3078881B2 (ja) | 生体試料中の成分測定法 | |
JP4067147B2 (ja) | クレアチンホスホキナーゼ活性の測定方法及び試薬 | |
WO1997023643A1 (fr) | Methode pour determiner les acides biliaires conjugues avec l'acide sulfurique et kit prevu a cet effet | |
JPH03232498A (ja) | ニコチンアミドアデニンジヌクレオチドリン酸の測定方法 | |
JP3034984B2 (ja) | D−ガラクトースの高感度定量法および定量用組成物 | |
JP2000139494A (ja) | 複数の酵素を反応させる物質の定量方法及び酵素組成物 | |
JP2001231596A (ja) | 検体の溶血による影響を回避する測定方法およびその方法に使用される測定試薬 | |
JP3936976B2 (ja) | Ampの酵素的分解 | |
JPH1118798A (ja) | コレステロールの定量方法及び定量用試薬 | |
JPH0698035B2 (ja) | 体液中のカルシウム測定方法 | |
CN119000572A (zh) | 一种基于银离子-opd系统的三模式光学传感器制备方法及其应用 | |
Panteghini et al. | Evaluation of a new commercial assay kit for quantification of lactate dehydrogenase isoenzyme 1 in serum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002565130 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002712305 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002712305 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002712305 Country of ref document: EP |